Q4 2020 FMC Corp Earnings Call
Good morning, and welcome to the fourth quarter 2020 earnings call for FMC Corporation. This event is being recorded and all participants are in listen only mode share.
You need assistance. Please signal a conference specialist by Christmas and Starkey followed by zero.
After to pay today's prepared remarks, there will be and opportunity to ask questions.
To be placed and the Q&A queue. Please press the star key and one at any time, if youre using a speakerphone. Please pick up your handset before pressing the keys.
I would now like to turn the conference over to Mr. Michael Wherley Director of Investor Relations for FMC Corporation. Please go ahead.
Thank you and good morning, everyone welcome to FMC Corporation's fourth quarter earnings call.
Joining me today are Mark Douglas, President and Chief Executive Officer, and Andrew Sandifer, Executive Vice President and Chief Financial Officer.
Mark will review, our fourth quarter and full year performance and provide our outlook for 'twenty and 'twenty, one and the first quarter and Andrew will provide an overview of select financial items.
On the prepared remarks, we will take questions.
Our earnings release, and today's slide presentation are available on our website and the prepared remarks from today's discussion will be made available after the call.
Let me remind you that today's presentation and discussion will include forward looking statements that are subject to various risks and uncertainties concerning specific factors, including but not limited to those factors identified in our earnings release and in our filings with the SEC.
Information presented represents our best judgment based on today's understanding actual results may vary based upon these risks and uncertainties.
<unk> discussion and the supporting materials will include references to adjusted EPS adjusted EBITDA adjusted cash from operations free cash flow and organic revenue growth all of which are non-GAAP financial measures.
Please note that as used in today's discussion earnings means adjusted earnings and EBITDA means adjusted EBITDA.
A reconciliation and definition of these terms as well as other non-GAAP financial terms to which we may refer during today's conference call are provided on our website with that I'll now turn the call over to Mark.
Thank you Michael and good morning, everyone.
Let me start by saying the fourth quarter was an unusually difficult one for our company and we are disappointed and our earnings results.
We exceeded the midpoint of our guidance on EPS and EBITDA for a long stretch of Cortez, principally because of the strength of our portfolio and our geographic balance combined with strong execution and the face of extreme weather events and significant interest industry specific supply chain disruptions.
This quarter was an anomaly and we will be as transparent as always to explain what happened.
We experienced significant logistics and supply chain constraints and the U S reduced demand and the U S. On some lower value besides lower demand in Brazil, and Argentina. Following the drought related delay to the start of the season and products that were held up and Argentine customs on.
On the positive side, we saw strong growth in EMEA and once again broad growth in Asia.
We had a very strong quarter from a cash flow perspective, which led to full year free cash flow of $544 million and 80% increase over 2019.
We also posted very solid 2020 overall results. Despite numerous challenges related to the COVID-19, pandemic and $218 million and revenue headwinds from foreign currencies.
Our organic revenue growth of 7% and our 2% EBITDA growth shows how aggressively we managed costs and implemented price increases to offset as much of that FX headwind as possible.
The guidance for Q1 reflects our view of the environment in Brazil, as well as continued logistics and supply chain disruptions are carrying around the world.
We believe these COVID-19 impacts other perhaps as severe as at any point over the last year.
In addition, although very strong Q1, and 2020 makes this quarter year over year comparison, a particularly difficult one.
All of FMC has manufacturing facilities and distribution warehouses remain operational and fully stuffed despite the ongoing pandemic.
However, one of our U S toll manufacturers was disrupted in Q4 because of Covid related staffing issues and illustrating just one of the ongoing business risks during the pandemic.
We successfully completed the implementation of on U S. H P system in November.
We now have a single modern system across the entire company for the first time and all the history, which is enabling significant efficiencies and our back office processes.
And finally, we get a thorough technology update to investors on November 17.
Highlights and the increasingly positive impact and Houston that chicken and biological active ingredients will have on our business over the next decade and the ways in which we are driving to be the leader in crop protection innovation.
We plan to launch seven new active ingredients and four new biologicals this decade.
Which we expect will contribute a combined one eight to $2 $1 billion and incremental sales and 500 2030.
We recently announced a new collaboration with Novozymes, a world leader and enzyme discovery and production to research and co develop and commercialize biological enzyme based crop solutions for growers around the world.
This adds to research collaborations and partnerships signed in 'twenty, and 'twenty with zymogen and cyclical income.
And use our trend of investing in new and innovative technologies that will enhance our longtime and competitiveness.
Turning to our Q4 results on slide three.
We reported $1.15 billion in fourth quarter revenue, which reflects a 4% decrease on a reported basis and 2% organic growth.
Despite those headwinds we posted double digit sales growth and Asia led by India, China, Japan and Australia.
And in EMEA with double digit growth across a broad set of countries.
Adjusted EBITDA was $290 million, a decrease of 9% compared to the prior year period.
EBITDA margins were 25, 2% a decrease of 150 basis points compared to the prior year.
Adjusted earnings were $1.42 per diluted share in the quarter, a decrease of 19% versus Q4 2019.
This year over year decline was primarily driven by the decrease in EBITDA.
And increase in tax rate compared to the very low tax rate in Q4, 2019, and slightly higher D&A, partially offset by lower interest expense and lower non controlling interest.
Moving now to slide four Q4 revenue decreased by 4% versus prior year, driven by a 5% FX headwind and a 3% volume decrease.
Price increases contributed a positive full per cent impact and offset 80 per cent of the FX headwind.
The highest in the past few quarters to deliver a positive 2% organic growth.
Volume growth in EMEA, and the Asia was more than offset by weakness in North America and Latin America.
Sales and EMEA increased 45% year over year and 42% organically.
We saw particularly strong demand for next for insect control applications for specialty crops as well as herbicides for cereals, especially in France, Spain, Russia and Germany.
We also had significant growth and the U K as customers secured orders and that.
And so Brexit.
And Asia revenue increased 11% year over year, driven by both volume growth and India, China, Japan and Australia.
India saw strong demand and rice, and pulses and the south and in sugarcane and the north.
In addition to the growth from our recent market access expansion activities.
Last earnings call, we highlighted India is a key pillar of growth in Asia.
And the strength, we saw in Q4 exemplifies this potential with India growing over 25% organically and the quarter.
China saw robust demand for di and light insecticides, and fungicides on fruit and vegetables.
Growth in Australia was driven by demand and herbicides for cereals, and oilseeds, while Japan and strength came from a variety of insecticides.
Moving now to Latin America sales decreased 9% year over year, but grew 4% excluding significant FX headwinds.
Rising actions across the region offset about 50 per cent of the currency headwind and at the earnings level in Q4 substantially more than in the prior two quarters.
The Brazil season was delayed by at least that two days due to the hot dry weather and this delay meant many numerous crops missed applications that will not return.
The drought persisted throughout Q4, resulting in lower than and I expect to defend and across many crops and it also impacted Argentina and other countries and the region.
But Latin America or overall, we estimated the drought reduced sales by about $2 million.
Argentina, We also had about $10 million of products held and bonded warehouses that was not released by customs officials and a timely manner.
Although these factors reduced Q4 growth and Argentina, 'twenty and 'twenty was still our best year ever for the country.
And North America sales decreased 34% year over year.
$40 million of this decline was due to supply chain disruptions, including Covid related factors associated with logistics and it's all on manufacturing partner <unk>.
Impacting our ability to meet demand late in December.
And additional $30 million of the decrease was due to reduced volume and some lower value pre emergent herbicides.
And you are herbicides, such as authority edge authority suite cream and Max.
And you to add value and grow well.
We should also note that all biologicals business had a very strong Q4 with sales up in all regions by at least a high teens percentage, including very songs and strong sales of Corso and Brazil, and successful launches of our cuda and and the EMEA and on supply and an M. A C S and South Korea.
Turning now to the full quarter EBITDA bridge on slide five.
We had a $50 million contribution from higher pricing, which was nearly double what we realized in Q3.
We also aggressively managed costs to offset and nearly all of the $30 million a year over year headwinds we had anticipated however.
However, the ethics headwinds were more severe than I expected and the late volume misses and North America, and Latin America were too large to overcome.
Moving to slide six for a review of our full year results, we reported $4 six $4 billion and revenue, which reflects a 1% increase on a reported basis and 7% organic growth rate.
Adjusted EBITDA was one point to $5 billion and increase of two per cent compared to 2019, even with nearly $217 million and headwinds from FX.
EBITDA margins were 26, 9% and increase of 40 basis points compared to the prior year.
2020, adjusted earnings was $6 19 per diluted share and increase of 2% versus 2019. This.
This increase was driven by the increase in EBITDA as well as lower interest expense and lower share count offset partially by a higher tax rate compared to the very low tax rates and the prior year and higher DNA.
Turning to slide seven for some of the drivers behind the full year revenue growth.
Overall volume contributed four percentage of revenue growth, while price increased sales by 3%.
About $50 million of the 'twenty and 'twenty revenue growth came from product launches within the year.
And Asia sales increased 6% year over year and 9% organically.
Market expansion and share gains and India, coupled with a very strong market rebound and Australia with the primary drivers.
And our diamonds were and high demand throughout the region in 2020, as we continue to grow and specialty crops, such as rice and fruits and vegetables.
Sales and EMEA grew 4% versus 2019 and 6% organically.
Demand was driven by dialogues on specialty crops Battle Delta herbicide on cereals, and spotlight plus herbicide on potatoes.
Latin America posted a 1% year over year revenue growth, but high single digit volume growth and solid price increases led to 17% organic growth.
Brazil had robust demand for our products for soybeans and sugarcane, while there was reduced demand and acreage foot column.
North America sales decreased 8% as we had channel Destocking and the first half and then a tough Q4 as described earlier on.
Note the Lucentis fungicide launch had a strong second gear and <unk> insect control had a good loans yet.
Yeah.
Moving to slide eight where you can see how our full year EBITDA bridge.
William contributed 9% to the growth while the combination of stringent cost controls and price increases offset 70 per cent the impacts of foreign currencies.
Turning now to slide nine and I look at the overall market conditions for 'twenty and 'twenty one.
We expect the global crop protection market will be up low single digits on a U S dollar basis.
Commodity prices for many of the major crops are higher and stock to use ratios and improved compared to this time last year.
All regions are seeing some benefit from better crop commodity prices, while the impacts from COVID-19 on crop demand appear to be lessening.
Growth in Asia is expected to be and the low to mid single digits, driven by India, Australia and ASEAN.
Favorable weather should contribute and many countries.
The weather related recovery and Australia is expected to continue.
The other three regions are each projected to grow in the low single digits.
And the Latin American market will be strengthened by price recovery from FX headwinds from 2020, and Brazil continued strength and the soybean market and increase of fruit and vegetable exports from Mexico and more normal weather patterns that are forecasted across the region.
And the EMEA market, we are seeing a solid market for cereals, and specialty crops, which should be helped by improved weather and several parts of the region.
The market in North America is projected to have a firm foundation from crop commodity prices, but we are seeing a trend of distributors and retailers looking to strategically reduce their own inventory levels.
The specialty crop market as stable, but the most significant change and demand will depend on the pace of the economic recovery.
Taking all the above into consideration we view 2021 is a more positive and macro environment and we did this time last year.
Having said that we are all too well aware of the potential disruption that COVID-19 and whether couldn't calls and at any one quarter.
Turning to slide 10, and a review of Fmc's full year, 2021, and Q1 earnings outlook.
FMC full year, 'twenty, and 'twenty earnings and I would expect it to be in the range of $6.65 to $7.35 per diluted share a year over year increase of 13% at the midpoint.
Consistent with past drunk, just we do not factor in any benefit from planned share repurchases and our EPS estimates.
2021 revenue is forecasted to be in the range of $4 90 to $5 $1 billion and increase of 8% at the midpoint versus 2020 and 9% organic growth.
We believe the strength of our portfolio will allow us to deliver this organic growth continuing a multiyear trend of above market performance.
EBITDA is expected to be and the range of 1.32 billion to $1 four $2 billion, which represents a 10% year over year growth at the midpoint.
Guidance for Q1 implies year over year sales contraction of 7% at the midpoint on a reported basis and 5% organically.
We all forecasting and EBITDA decline of 15% at the midpoint versus Q1, and 2020 and EPS is forecasted to be down 18% year over year.
Turning to slide 11, and full year EBITDA and revenue drivers.
Revenue is expected to benefit from 7% volume growth with the largest growth in Asia, and a 2% contribution from higher prices.
She is forecasted to be a 1% topline headwind.
We are expecting gross broad growth across all regions.
Asia has the best overall fundamentals, but we're also seeing the benefits of better weather and Europe strong soybean outlooks for both Latin America, and North America, and a cot and recovery and Brazil next fall.
Because of these factors we are expecting a very strong second half of 'twenty and 'twenty 'twenty 'twenty, one relative to the first half.
New products, such as Overwatch, herbicide and Australia based on our ice and flex active and XI way fungicide and the U S are expected to make meaningful contributions and we are also launching flow into Pierre fungicide and the U S for non crop applications.
We are forecasting a strong year for each of our product areas and.
In addition to continuing strength over and ask the parents I as it for insect controls and.
<unk> growth is also expected to come from products, such as TV, and then hero and Avatar herbicide should see growth and several of our top brands, including authority Gammage reactor and spotlight plus in addition to the Overwatch launch and growth and fungicides is forecasted to be driven primarily by the XI launch in the U S.
Our EBITDA guidance reflects strong volume and pricing benefits offset partially by increases in R&D spending as well as the reversal of some of the temporary cost savings from 2020.
We are forecasting and $40 million increase in R&D to bring us to a level of funding that keeps old projects on the critical path to commercialization.
Additionally, we're making growth investments and al Salam intelligence and other precision AG initiatives, new product launches like Overwatch as well as FMC ventures.
We are also expecting some supply chain cost increases, including logistics and pockets of raw materials.
These headwinds will be partially offset by the realization of the final $15 million of Sap's synergies, which will give us a cumulative S. A P synergies of approximately $65 million.
Moving to slide 12, where you see the Q1 drivers.
On the revenue line volume is expected to drive a 6% decline, while a 1% contribution from higher prices largely offsets the FX headwind.
We expect the benefit of approximately $25 million and sales from Q full supply and logistics delays to be captured in Q1. This is about half of the Q4 impact.
And the U S. This miss timing limits, what we can recoup and then Argentina ongoing customers delays and releasing products could cause us to miss application windows.
There are several headwinds in Q1 revenue that more than offset the flow through from Q4.
Thus, we are facing and particularly difficult comparison, and Latin America, where sales increased 26 per cent year over year, and 38% organically in Q1 and 2020, Brazil.
Brazil's cotton business was very strong for us a year ago. This will not be repeated this season, that's called on acreage is down 15%.
In EMEA, we are facing continued headwinds from discontinued registrations and the $15 million and Q4 sales related to Brexit, but would normally it's being sold in the first quarter.
Regarding EBITDA drivers reduced volume is the biggest factor while pricing is forecast to offset the FX headwind.
Costs are expected to be higher by $12 million driven primarily by the increased R&D investments we mentioned earlier.
With that I'll now turn the call over to Andrew.
Thanks Mark.
Let me start this morning with a few highlights from the income statement.
FX was a five per cent headwind to revenue and the quarter as expected with the impact of higher than anticipated local currency denominated sales and Brazil offset in part by modest tailwind and the Euro zone.
For full year, 'twenty and 'twenty FX was a six per cent headwind to revenue.
The first day and Royale represented the vast majority of the FX headwinds in 'twenty and 'twenty, followed by the Indian rupee, Pakistan rupee, and a broad number of non euro currencies and a map.
Pricing actions offset slightly half of the currency headwinds and the year.
Looking ahead to 'twenty 'twenty, one we expect a more stable FX environment with only a slight headwind at revenue we.
And we will continue to take pricing actions and Brazil to recover the FX impacts from 'twenty and 'twenty, but overall pricing will be somewhat dampened by price volume choices being made and our Asia business to drive higher growth.
Interest expense for the fourth quarter was $34 $2 million down $8 $7 million from the prior year period benefiting from lower debt balances and lower LIBOR rates Andrew.
Interest expense for full year, 'twenty, and 'twenty was down $7 $3 million from the prior year with the benefit of lower interest rates, partially offset by changes in debt outstanding.
Our effective tax rate on adjusted earnings for 'twenty, and 'twenty was 13, 7% well within our expectations and up from the very low 2019 rate due to shifts and the geographic mix of taxable earnings and interrelate and impacts on the U S minimum tax on foreign earnings.
The tax rate and the fourth quarter was $14 four per cent to true up with the full year actual rate.
Tax was a headwind to earnings and the quarter due to the very low tax rate and the prior year period.
We expect our effective tax rate to be and the range of $12 five to 14, 5% in 'twenty and 'twenty, one similar to 'twenty and 'twenty.
Moving next to the balance sheet and liquidity.
Gross debt at year end was $3 $3 billion, essentially flat with the prior quarter and nearly $600 million of cash on hand.
We chose to hold cash on the balance sheet and advance of the seasonal working capital build and we see and the first quarter to avoid having to take on as much commercial paper and the beginning of the new year.
As such gross debt to trailing 12 month EBITDA was two six times at the end of the year, while net debt to EBITDA was two three times.
We are comfortable wearing the right leverage range given the excess cash at year end.
We do not expect to carry this level of cash on a steady state basis going forward. So you should expect cash balances to decline through the coming year.
Moving to slide 13, and a look at 'twenty and 'twenty cash flow and the outlook for 'twenty and 'twenty one.
Free cash flow for 'twenty, and 'twenty and was $544 million with free cash flow conversion from adjusted earnings of 67% both metrics up 80% from the prior year period.
Adjusted cash from operations increased by about $170 million, and 'twenty and 'twenty with growth and working capital more than offset by lower and on working capital factors and increased EBITDA.
Capital additions were down $60 million due to project delays and deferrals related to the COVID-19 pandemic.
Legacy and transformation spending was down $14 million with relatively stable legacy spending and transformation spending lower as we completed our SAP implementation.
We anticipate full year, 'twenty and 'twenty, one free cash flow to be and the range of $530 million to $620 million and increase of 6% at the midpoint with free cash flow conversion and 63 per cent at the midpoint.
Gross and adjusted cash from operations and reduced legacy and transformation spending are expected to be partially offset by a significant year over year increase and capital additions.
This increase and capital additions comes as we catch up on projects that were delayed or deferred and 2020 due to the pandemic.
Turning to slide 14.
We're pleased with our strong free cash flow growth and improvement in free cash conversion.
There are a number of moving parts and our 'twenty and 'twenty cash flow results and 'twenty and 'twenty outlook and merits. Some further discussion and will help better explain this trajectory.
'twenty and 'twenty free cash flow benefited from a planned real estate asset sale that will not repeat as well as the on forecasted delay of a lump sums environmental liability payment and we had expected to be paid in December.
Excluding these impacts 'twenty and 'twenty free cash flow would have been about $500 million and cash conversion about 62 per cent.
Similarly, 2021 free cash flow and negatively impacted by the timing shift of the environmental liability payments.
Adjusting for this timing shift 'twenty 'twenty, one free cash flow would be about $600 million and cash conversion and 65 per cent.
So on a more comparable basis free cash conversion steps up from 38 per cent and 2019 to 62 per cent in 'twenty, and 'twenty and 65% in 'twenty and 'twenty, one getting closer to our 70 to 80 per cent target range for 2023.
I know that this view of cash flow, we've not made any adjustments for the abnormally low capital additions in 'twenty and 'twenty or the catch up to a more normal level in 'twenty and 'twenty one.
But this shift is in large part the reason why cash conversion steps up more slowly in 'twenty and 'twenty, one as we increase and capital additions largely offsets the step down and transformation cash spending from the completion of the S. E T program.
And you should expect the capital additions continue on a similar range to 'twenty 'twenty one for the next several years to support our organic growth, including new capacity to support new active ingredient introductions.
Equally as important as growing our free cash flow and the discipline with which we deploy it as.
As you can see on slide 15, we continue our balanced approach to cash deployment.
We are fully funding, our organic growth and making modest inorganic investments to enhance our gross.
We are and then returning excess cash to shareholders through dividends and share repurchases, while keeping debt at our targeted leverage levels.
And 2020, we deployed nearly $350 million of cash flow, while maintaining excess liquidity throughout the pandemic.
We deployed $65 million to acquire and the remaining rights to the fungicide for them and up here, we paid nearly $230 million and dividends and we repurchased $50 million and FMC shares and the fourth quarter.
And 2021, and we expect to accelerate cash deployment.
We are planning to repurchase between 400 and $500 million worth of FMC shares and the air with purchases and every quarter of the year the more heavily weighted to the second half.
We expect to pay dividends approaching $250 million and we will continue to look for attractive opportunities to make additional modest inorganic investments to complement our organic growth and expand our technological capabilities.
I'd like to close with a final update on our S. E. T S forehand on ERP system implementation.
And successful Alaska alive and November and are now operating on a single thoroughly modern system across the entire company for the first time and our history.
The go live went better than expected and we have smoothly transitioned to operating the company and closing the books and the new system.
Our new assay system has enabled significant efficiencies and our back office processes with.
And we captured over $50 million and synergies and 'twenty and 'twenty, having moved aggressively to accelerate $30 million and planned savings from 'twenty 'twenty, one 'twenty and 'twenty.
We now expect to deliver $15 million and S. E. T enabled synergies in 'twenty and 'twenty, one the benefit of which is reflected in our full year guidance.
For a total of $65 million and synergies from and implementing the new system.
There will certainly be additional efficiency gains in 'twenty and 'twenty, two and beyond as we further leverage this generational investment and our business process infrastructure.
But we will drive them as part of our business as usual efforts to gain leverage on back office costs as we continue to grow the company.
And with that I'll turn the call back over to Mark.
Thank you Andrew.
We had a number of issues and late Q4 that we're having to address we do not expect all of them to the result in Q1, we do however, see these issues as transitory and are focused on ensuring we can mitigate supply chain risks and continue to expand on market growth opportunities.
As you can see from our robust 'twenty 'twenty one guidance, we are confident the 'twenty 'twenty, one will be another year of strong revenue and earnings growth for FMC.
We continue to renew our portfolio launching two new important products and Q1, we continued to invest and our R&D pipeline and we remain fully committed to bringing new sustainable technologies to our customers.
Our overall agenda on sustainability continues to advance with the recent appointment of on our first chief sustainability officer and through new partnerships like the one recently announced with Novozymes.
We plan to return about $700 million to shareholders this year through dividends and buybacks.
And finally without 'twenty 'twenty, one growth rates above the long range plan, we remain firmly on track to deliver our five year plan commitments.
Before I close I'd like to highlight the press release issued yesterday regarding Pierre Broncos retirement as executive Chairman effective April 27th.
Very much appreciate his leadership and look forward to his continued involvement as nonexecutive chairman.
I'll now turn the call back to the operator for questions.
Thank you we will now begin the question and answer session.
Can be placed and with queue. Please press the star key then one on your Touchtone phone.
And we're using a speakerphone please pick up your handset before pressing the keys.
Please limit yourself to just one question only.
You have additional questions you can jump back on the queue.
To withdraw from the queue. Please press Star then two.
At this time, and we will pause momentarily to assemble all else too.
Okay.
And the first question will be from Chris Parkinson with Credit Suisse. Please go ahead.
Great. Thank you.
Many of us on interpret as a fairly cautious.
<unk> Guide you are maintaining your organic revenue growth. Despite some challenges you won't provide.
And you long prided yourself on geographic balance and crop diversity.
So can you just hit on the two to three highlights with break this year and.
It seems like Youre basically constructive on each one and still and costs up and MS music on certain other regions and emerging Europe.
Any color to help us bridge and help investors sense was weaker than expected once U.
Versus what should be characterized as still a fairly strong year. Thank you.
Yeah. Thanks, Chris.
Listen it's fairly obvious when you look at the release that you know what we have we have a weak Q1, yet a very strong full year and and certainly from our perspective, you know when we look at what is going on in Q1. It does bear some relationships to what is happening in the second half of the year and and I'll give you some color on that.
First of all you know when we talk about some headwinds in the quarter you look at what is happening in Europe, we have we have headwinds from a.
Lots of registrations. It happens all the time it just so happens that about 50 per cent of the total revenue that is lost and the whole year, because in Q1, and Europe and Thats just purely down to the types of products that are sold in Q1 and the timing. So that's one element that that's somewhat unique.
I think the second one is really all around less.
And America.
We highlighted in the script that we had a very strong cotton business last year and it really was strong and this year. It is it is Lola the acreage is down we do have some lingering effects from the the drought and missed opportunities.
But that all rolls together, very importantly, and it's something that we didn't highlight and the scripts, but something that operationally, we're managing very carefully we are watching and managing inventories in Brazil very carefully.
There is no way you go through our fourth quarter like we did with 30 days delay I mean put that in perspective.
All he beans take 110 days to grow we had a 30 day delay.
Now that means that some sprays get missed those products were already in the marketplace. They didn't get used.
We've told you many times that we manage inventories very carefully we see that our inventories are elevated.
They're nowhere near as bad as they were five years ago.
But the industry is elevated as well we are making a decision in Q1 two.
Deliberately sell out of inventory and make no mistake, we're selling nicely in Q1 E. D. I L business on the ground is actually up year on year, but we are not replenishing those inventories and why are we making that decision now because it makes the second half of the year and our position and the market place much stronger.
We still want to recover price, we didnt fully recover all of the price in 'twenty and 'twenty. This reduction of inventory puts us in a much better position to get price increases and Q3 and Q4.
I like the fact that we already see today that the industry is moving on price. There are many more companies signaling to the market place with lessons that are public that they all moving on price. We are doing the same so it's very deliberate we could make a decision we could sell and have a more normal Q1 and less of it.
America, and particularly in Brazil in Q1, all we can reduce the sales today sell out of inventory and have a much stronger season 'twenty one 'twenty two.
There are some other facets as well to the second half that we should highlight.
Our growth and Asia is weighted towards the second half of the year, you've already talked we've already talked about India. A couple of times over the last calls India was very strong in Q3 and Q4, we expect that to continue.
We've talked about investing in India to get us a better market access and underrepresented regions of India.
That continues and will bear fruit as we go through this year.
A lot of different crops involved the rices pulse sugarcane fruits and vegetables, and more importantly, I saw and market access gross we're growing our herbicide portfolio as well, introducing new mixtures, especially and says sugarcane corn and soybeans. So India is expected to continue that very strong growth path and the.
Second half of the year.
And I like to the fact that you know and the ASEAN region, we're seeing much better conditions in Vietnam, and Thailand, as we drive our rice business and our fruit and vegetables business, we see and Indonesia with much better weather conditions, and again very similar to India growing our market access and Indonesia to geography, as well, we're not presence and.
Day, once again insecticide sales and herbicide sales on a variety of crops and then in China. We see continued momentum as we develop our enoxaparin die and large business and in China, and then lastly, you know not only do we expect Brazil to be stronger and the second half given the moves we're making.
Other parts of the region are doing very well for us. We can we continue to expect Argentina, we'll grow our crop exposure is getting better the portfolios, we're introducing a batch of products there and.
And North America, frankly, with what happened in Q4, we should have a much easier comp in terms of our volumes.
So we see that as a very key driver and Q4, and then you know and and Europe. We expect a strong Q3 on cereal herbicides, we are developing and nice position on cereal herbicide you've heard me talk about battle Delta.
That's a product that's growing well and we had a very weak Q3 last year due to weather on cereal. So this year, we expect much better conditions you put all that together you can see why we're much bullish for the whole year, but you can see while we have a very different profile Q1 through Q3 Q4, I know, that's a very long and so.
And to a very simple question, but I think it's worth getting it out there because I'm not surprised you asked that question first Chris but the reality is we're setting ourselves up for a very strong second half of the year.
No that's very fair as always thank you for the color Mark.
Okay.
Thank you and the next question will be from Adam Samuelson with Goldman Sachs. Please go ahead.
Hi, Thanks, good morning.
Tony.
And maybe following up on some other color Mark and you just gave in response to Chris which was incredibly helpful and just thinking about kind of how the fourth quarter and played out there was a I mean, you came short of kind of where the initial guide had been by that.
$55 million and.
And on EBITDA, and and I just wanted to clarify that the expectation is given the timing you don't necessarily get most of that back.
And.
'twenty and.
And in 'twenty, and 'twenty, one and I guess and then maybe additional kind of Mark Hill or that there were some allusion to distributors, reducing inventory in North America, and maybe just elaborate on that point a little bit it would be helpful. Thank you.
Thanks, Adam Yeah listen the first piece you know I think we're saying we're getting all of the materials that we had supply chain disruptions through we're getting about half of that back and and.
And Q1, the reality is listen it's a competitive world customers wanted to place orders you deliver material if you Miss the delivery and some customers will wait somewhat and the reality is we did lose some sales we consider that transitory we don't expect that to happen in Q4 next year.
Team the commercial team will be working hard to recoup that position and we're very confident that the products that we have to deliver then we'll deliver.
The comments on distributor.
And distributors and retailers in the U S.
We've watched this evolved over the last year or so and you know as growers faced lower income supply chains of of being squeezed a ball and I think frankly, I think many of us at what point and the value chain and distribution and retail are paying much closer attention to working capital so the cash.
We're making them all broad based and it's something we're aware of we will work with our customers under these circumstances and it's what we do but were highlights and get out that because we believe it's a fact that for the industry that needs to be highlighted because everybody's talking about strong commodity prices and how everything is going to grow rapidly and the U S.
And that may well be true and certain segments, but let's not forget there is a value chain here that needs to make money and the balance sheets are important to many of other customers and that will get managed appropriately. So that's that's why we made that comment because we do see that trend and increased focus on working capital and balance sheet.
All right, that's really helpful and if I could just sneak in a quick follow up as we think about pricing over the course of the year I guess on one hand, this and carryover pricing from the actions and Brazil, and South America that you took and the second half, but it seems like the pricing side of things is gonna be more and more back half weighted as well.
That sector.
Yeah. I mean, you you think about you know we're entering once we hit Q3, we enter a whole new season in Latin America.
And that's clearly where we're looking to recover most of the of the lag that we had and in 'twenty and 'twenty, it's normal it happens year to year.
But we're very confident that we will we will get it we do have pricing and the first half of the year. We have about a third of the total for the full year is and the first half to the second half, but really it follows the seasons and Latin America is the big season.
I like to some some.
Some pricing in Europe, as well, but mainly Latin America.
Alright, that's all out and really helpful. I'll pass it on thank you. Thank.
Thank you.
The next question will come from Stephen Byrne with Bank of America Securities. Please go ahead.
Yes, good morning, Mark here 2021, and outlook things that are low single digits on increase in most regions your own organic revenue growth.
Near double digit high single digit.
I'm curious to hear your and your view or.
On Directionally and how do you think about those estimates changed and the last six months, if we roll back six months.
And your month to choose for corn, and soybeans, wheat, and cotton and more all significantly lower.
Corn may not be a big crop for you, but it's nearly doubled and not much time, how would you say that.
And the use of crop chems in 'twenty and 'twenty, one and Jay.
Potentially increased application rates, what would be dragging day.
But low single digit market growth.
And potentially more tolerant to how youre pricing that's driving that.
Just curious to hear your views on on the impact and crop commodity prices.
Yeah. Thanks day.
I think I. Thank all of you over the last year as that's become more optimistic because we've gone along we've been we've been forecasting for the last few years sort of a flattish type market and frankly, we've been pretty close to where the market is is really finished up and.
And you can tell by all of our organic growth rates and on revenue growth rates that you know we are above the top and at our our five year plan and sort of numbers. So we do consider it a good year clearly when you when you have strong commodity prices like we see grow is all going to spend money to protect the crops. They want the highest yields.
Therefore, they get the most value. So I think it's going to be a combination of a couple of things price recovery and Latin America. As I said he is going to be important. The good news is Brazilian growers argentinean and growers are the <unk>.
Mexican fruit and veg grow as they're all and much better shape than they were 12 months 18 months ago. So that feeling confident we do expect to see acreage increase and in Latin America on top of on top of the good prices. So all you should be increased we would expect.
Cotton to bounce back quite considerably next year. So I think it's gonna be a more of a combination impact of price and in Latin America, and then really maximizing our customers' ability to get the highest yields by using the best products and you know frankly, and that's why our Diamide and one of the reasons all day.
<unk> has been doing per well around the world is the fact that they do enhance yield and allow the growers to get that productivity. So bottom line for me Steve I think we are more confident that we were 12 months ago. These growth rates are higher than we would've had 12 months ago for 'twenty and 'twenty, one and we're confident that all grow as customers.
I'll go on to be looking for the best solutions to improve yield.
Thank you.
The next question is from Vincent Andrews with Morgan Stanley. Please go ahead.
Hi, This is Steve Haynes on for Vincent.
Just want to ask a question on some of the Covid related costs that are coming back up.
Can you quantify how much is coming back and maybe what the risk might be and in either direction for that number.
Yeah, you know when we are when we look at where we are today and we think about that $19 million of of cost that we have a year over year, we think roughly about $25 million to $30 million is really what we would call Cogs increases you know I was very deliberate and my comment.
And it's that we do see disruptions and logistics costs that are higher than they have been at any time you can go and look at our you can go and look at any of the day throughout that and look at shipping rates and Shanghai, It's a rough sit down on a year ago was about $1700 of container it's now $9300.
Container that is real increase but we simply don't control, we can try and mitigate that as much as possible, but there are real logistics costs out there that are starting to flow through many industries and this is not peculiar to our industry or even FMC we.
And we hear about it and see about it and many other industries I think the other pieces, we are starting to see some raw material and active ingredient increases coming out of China. It would appear that parts of China, and particularly the null of had supply constraints due to pockets of Covid and those are starting to ripple.
Through so we've been very careful on raw material costs, but we do believe we will see higher raw material costs not across the board, but in pockets through 2021. So that's how we kind of get to that $25 million to $30 million increase it's not broad based it is more pockets of activity, but I do think.
And you're going to hear more about it as more people get into the year and talk about their cost structures.
And our next question will come from Mark Connelly with Stephens. Please go ahead.
Mark I was hoping you could give us an update on your diamide licensing and partnership.
So you have a whole lot of those and also on where your capacity expansion plans and maybe tell us how have you done on my portfolio performed in 2020.
Yeah sure Mark so on on the first one with the with the Diamide third party relationships they are continuing to evolve.
I think the last time I gave you an update we said we had about 40 to 41 agreements around the world that number is up to about 50 today.
And so you know commercial teams are continuing to develop those local relationships as well as as well as some of the global relationships that we have.
You don't die and lives has grown very strongly as you and everybody else knows last year. I think we finished just north of $1 $8 billion and revenue and size up from an initial.
$1 $1 billion, when we acquired the business. We I think the business grew in the <unk> and the mid to high single digits last year closer to the high single digits on on organic basis, it would be even higher than that we just don't track it at the product level.
So very successful you know the registration side of this I've talked about and the cost and it and it continues to evolve you know when I think about 'twenty and 'twenty between <unk>.
And as it there and <unk>, we had over 70 brand new registrations in the year and.
That is essentially driving you into new geographies I think there's something like 21 brand new crops added with those registration. So those of crops that we've never been on before so you can see why we keep that registration.
Portfolio very close to hot because that's one of the key drivers not only do we have to keep the market access going but we also have to get those brand new registrations.
From our perspective, we track it very closely.
I could give you I'll throw you some numbers out there that you may find interesting and 2018.
And we had 106 <unk> registrations around the world.
We are now at 173.
And then you know when you look at and you look at for an exit Bill. We had 170 in 2018 went out 250. So people often ask why does that matter. It gets you new access.
And it gives the commercial groups Nu Mark has to go sell against older Chemistries that are out there. So I expect that growth rate to continue as we've said for and then he is as we go forward.
At some point this year, probably and the oldest coal or yeah, probably the oldest coal will give more details around the third party relationships where are they going what are they encompass I think we owe that to our investor community, we've talked about it and sort of a high level I think it's time now.
We have over 50 of these in place. So we have to start giving some more granularity here.
Super helpful. Thank you.
And the next question will be from Laurence cooperating with Exane BNP. Please go ahead.
Thank you and good morning on Mark I've got a question on the change outs.
Thank you historically, you've talked about one to two per cent impact on full year and I was wondering <unk> 'twenty 'twenty, one and is expected to be.
And much bigger than that and also can you talk a little bit the balance.
The product categories and he told in Europe for instance, and any color on that would be helpful.
Yeah. Thanks Laurel.
We are forecasting about.
And 2% headwind due to registration losses.
Interestingly enough this year.
Last year. It was heavily heavily focused on Asia and parts of Latin America. This year, it's roughly split 50 50 between Europe and Latin America, It's a combination of some older insecticides and some older fungicides slasher besides nothing.
Nothing that's really big not like when and 2019 and when we.
Remove carbofuran, which was the bulk of what we saw the impact last year. This is more a myriad of smaller products.
Somebody's deliberate on our site cleanup of the portfolio reducing that portfolio impact.
But frankly, there's no major one it's a I would probably say six or seven different compounds spread across that 2%.
I think that's a fair rate and all we've talked about a roughly on average about a one and a half per cent drag due to registration or deliberate actions by ourselves and the last couple of years or pretty close to about two per cent range don't have a good view yet.
2022, our regulatory team will be telling us what that looks like but I think for your modeling you know you should plug in that 1.5% to 2% sort of drag going forward on a on a longer term basis.
Okay. So it's almost 4% on Q1 and then.
I guess, that's hits you on but yes it can.
Yeah, it's much higher in Q1, because about 50 per cent of.
The European impact, which is roughly half of the 2% Z and Q1 and so it's a bit is a bit of a higher.
Bit of a higher lumpiness in Q1 that it would be the rest of the year Laurel.
Okay. Thank you.
The next question will be from Joel Jackson with BMO capital markets. Please go ahead.
Hi, good morning, everyone and.
And just a couple of questions. So Mark you talked about some missed opportunity I think you talked about some missed opportunities in court and in Brazil can you elaborate on that is that not just acres chef did you Miss some business or some share on court in Brazil, and then also are you seeing more generic pressure on generic pressure on GAAP stock in.
America, how is that playing into your forecast.
Yeah, you're right on cotton and Joel Cotton is not necessarily missed opportunity. It is lower acreage and the missed opportunity I was referring to was more on the soy complex and some other crops because of the drought caught on is purely around just 15% acreage reduction isn't enormous reduction and taught and in Brazil.
So hopefully that clarifies that for you on generics, yes, I have to say I think the low and develop pre emergent business, we are seeing more generic pressure and.
And our North American team makes decisions on an annual basis that they want to compete in that low end or are they continuing to focus their marketing efforts on the high and obviously this year. We decided we were not going to go take volume at low margin. It didn't suit what we wanted the business to look like it wouldn't have helped our inventory.
And that's for sure. So we decided to focus on the high and you know all authority suite premium authority Max and in actual fact, it really it really suits, where the market is going because you know as weed resistance builds and it is the tougher to control weeds that the growers are willing to pay the high premiums fall to them.
How you to get rid of those weeds the older formulations the mall, how shall I say.
And flow less sophisticated more generic formulations are not actually performing in those fields. So for us it's quite a natural lifecycle progression to move away from those generic products elsewhere and the portfolio I would say the generic pressures as probably as normal as it's always been a pre emergent we highlighted it because we.
Felt it was it was a significant event in the quarter and and needed to be needed to be talked about the positive to take from that is our formulation expertise moves us forward with new products that allow us to continue to take market share at the high end.
Thank you. The next question will come from Michael Sison with Wells Fargo. Please go ahead.
Yes.
Hey, guys good morning.
I mean.
Mark.
You give it out and you're doing a nice job, giving us the adjusted EBITDA Bridge for 'twenty one.
Looks like you'll you'll need about $180 million to Q2 and <unk>. So when you think about that $180 million.
How much of that is.
Seemingly within your control you've got some new products coming out and maybe a good portion of that the Diamide and then you know where do you think how much is at risk from sort of yeah.
Ill pass.
Past pressures and weather and and stuff like that.
Yeah, Mike listen I mean, you know when we forecast forward, we tend to forecast what we call normal conditions, so that would be normal weather normal pest pressures I mean, obviously the further out you forecast the more variance that could possibly be but today I would say there is obviously two pieces.
Volume and price.
I would say right now we're feeling very good about the price piece, given what we're seeing and Latin America and the marketplace from a volume perspective.
And also very confident given the fact that a lot of the growers are and much better position than they were 12 months ago and.
And you shouldn't underestimate the psychology of farmers that is a very important aspect to how they think forward how they will prepare for a strong season and what that means for us to feed that value chain.
As we get into the season, so obviously listen both price and volume we don't ultimately control they are part of the marketplace.
But I feel very confident that given where the business is positioning itself the new product growth the continued growth of <unk>.
Our ability to move price, which we've shown as we went through last year, we got that each quarter. It was higher than the last and you know we eventually ended up and not a bad place at all especially in Latin America. So just think of it in terms of I would say normal risk.
Yes weather will play a part as well pest pressure, but we're forecasting it to be normal and pretty confident of that forecast.
And thank you. The next question will be from Michael Picken with Cleveland Research. Please go ahead.
Hi, Yeah, good morning, and I'm just had a couple of questions in terms of you know just thinking broadly about kind of the trajectory of your EBITDA margins over the next several years and how much of the growth do you see coming from price mix improvements versus kind of the inflammation and a F.
And you know if attack the cost.
<unk> from China, or other costs and some of the raw materials increase how confident are you and your ability on kind of hold to preserve our margins and that type of environment for 'twenty and 'twenty one.
Yeah, Thanks, Mike listen at the end of the day when you think about our long range plan and five to seven and top line, 7% to nine and bottom line, we actually do that on a non adjusted FX basis I E. It's essentially a volume plan and if S.
Thanks goes against those will move price and that will adjust.
And the confidence you should have and 2021 relays itself at you know here. We are three years into our plan and we are right and the ranges where we should be despite the fact that in 2019, and we had something like $115 million of headwind on cost and in 'twenty and 'twenty. One we had about 200 and.
70 $218 million headway on FX, yet here, we are still in the middle of our planned range. So it's very it should give you a lot of confidence that we know how to manage these yes, you can have dislocations and of course, there obviously, but if you think about 19 2021, that's that's a very.
Strong track record of delivery with almost.
Close to if not more than $400 million of headwind over the three year period and.
Bill do you want to talk about costs sure Mike I think that's it.
As all as we've talked about for quite some time and it's a combination of both.
The faster growth of higher value products higher margin products as well as SG&A leverage on both.
From S&P synergies and just also from other leverage and growing the business and you're on that you've seen that trajectory. We were you know we were at a 25, 9% EBITDA margin in 2018 degree that expanded by 60 basis points, and 2019 expanded and another 40 basis points and 2020 and the face of the cost and FX headwinds Mark described and.
And at the midpoint of our guidance this year, we're expecting to expand margins and another 50 basis points, it's an and.
And next couple of years. It is still that balance story between SG&A leverage and mix improvement and it'll allow us to keep driving up that trajectory and a year.
Three of the five year plan, where at 150 basis points of margin expansion against the goal of 250 to 300.
And I would particularly in light of the headwinds we faced and we feel like we're exactly where we need to be on that trajectory and we feel very confident about continuing on it.
Thank you Andrew.
And the final question will come from Kevin Mccarthy with vertical research partners. Please go ahead.
Good morning, everyone and Mark I was wondering if you might elaborate on two items that you called out first the Brexit related boost the sales and EMEA in the fourth quarter and then secondly, the tolling issue that you cited in North America.
And you talk a little bit about the nature of that tolling relationship what the magnitude of it once and and the extent to which it may or may not be extending into the first quarter. Please.
Yeah sure Kevin So yeah, Brexit you know.
We have a strong business and the U K.
And we sort of think about it in terms of a roughly a $15 million to $20 million.
And a swing between Q4 and Q1 on a revenue basis.
And I have to say you know what when we put the plans in place with our customers.
And were skeptical that it would be needed, but given what we've seen in the U K and Europe with regards to freight and logistics and I'm very pleased we actually did that I know it makes Q1 look a little worse, but the reality is I'm glad we did it on the second piece with the toll manufacturing relationship. It is a it is a toll manufacturer that we've used for many years they were in it.
Particular hotspot related to Covid and simply could not get stuff and could not make the products that we needed and the timeframe that we needed it.
We are making some adjustments to our net worth so obviously help mitigate some of that.
We're not seeing that reoccurring in in Q1.
And frankly, most of that business, a cause and Q4 from a selling perspective anyway. So you wouldn't you wouldn't really expect it to see I think what it highlights for US as you know we do a very good job of mitigating raw material intermediate movements around the world, where we might have issues of course, we do and employ like many other companies many toll manufacturers.
And we really do have to we have to pay attention to every single one all the time. This one we did not have the right communication flow and obviously, we paid a price for that.
You can rest assured that we've learned the lesson there and it and it will not be happened and again, either there or outright anywhere else.
And then the second piece of that was you know the logistics element there was a lot of logistics issues in Q4 that we had to overcome some of it was related to lack of drivers and parts of the world. We've seen that in the U S and some of it was related to bowl warehousing, but the reality is you know the toll manufacturer was the big piece.
And that's all the time that we have for the call today. Thank you and have a good day.
Ladies and.
Gentlemen, this concludes the FMC Corp Conference call. We thank you for attending you may now disconnect.
Yeah.
Okay.
[music].
Yeah.
Okay.
Yeah.
Yes.
[music].
Yeah.
Yeah.
Yeah.
[music].